MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Adaptive Biotechnologies Corporation Total Assets 2011-2026 | ADPT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Adaptive Biotechnologies Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 513 M | 539 M | 661 M | 857 M | 923 M | 1.12 B | 912 M | 333 M | 362 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | 333 M | 691 M |
Quarterly Total Assets Adaptive Biotechnologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 491 M | 497 M | 511 M | 539 M | 559 M | 585 M | 620 M | 661 M | 718 M | 765 M | 791 M | 857 M | 884 M | - | 858 M | 923 M | 993 M | 1.03 B | 1.07 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B | 912 M | 912 M | 912 M | 912 M | 333 M | 333 M | 333 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | 333 M | 775 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Amgen
AMGN
|
90.6 B | $ 350.54 | 0.79 % | $ 189 B |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 19.39 | -0.56 % | $ 906 M | USA |
 |
Altimmune
ALT
|
280 M | $ 3.45 | 3.14 % | $ 304 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.62 | 0.21 % | $ 16.5 M | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
1.3 B | $ 219.22 | -1.2 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Benitec Biopharma
BNTC
|
99.6 M | $ 11.01 | 0.27 % | $ 453 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.12 | 1.44 % | $ 198 M |  Israel |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.58 | 3.95 % | $ 185 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Cellectis S.A.
CLLS
|
325 M | $ 3.39 | 1.5 % | $ 116 M | France |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
18.7 M | $ 0.6 | -1.79 % | $ 6.87 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
448 M | $ 12.85 | 0.86 % | $ 774 M | USA |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
CorMedix
CRMD
|
826 M | $ 6.43 | 2.88 % | $ 463 K | USA |
 |
Cara Therapeutics
CARA
|
126 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
7.94 M | - | -74.18 % | $ 955 K | USA |
 |
CytomX Therapeutics
CTMX
|
152 M | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
7.47 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
473 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
1.37 B | $ 21.1 | 4.59 % | $ 3.47 B | USA |
 |
Dyadic International
DYAI
|
8.22 M | $ 0.9 | -4.79 % | $ 25.9 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 4.29 | 1.06 % | $ 712 M | Canada |